DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 1 Smartsheet - 1 LSEG - 1 Sprinklr - 1 Mizuho - 1 there's - 1 StoneCo - 1 CH Robinson - 1
Top related locs:
Americas
Top related orgs:
Nvidia - 1 LSEG - 1 Revenue - 1 Mizuho - 1 JPMorgan - 1 Ultragenyx Pharmaceutical - 1 Goldman - 1 eBay - 1

Search resuls for: "Viridian Therapeutics"


2 mentions found


☆ Stocks making the biggest moves before the bell: Robinhood, Nvidia, Lululemon, Five Below and more
  + stars: | 2024-06-06 | by ( Alex Harring | ) www.cnbc.com   time to read: +4 min
Five Below told investors to expect between $830 million and $850 million, while analysts polled by LSEG forecasted $883 million. Sprinklr — The business technology stock dove 21.1% in the wake of weak guidance for the current quarter and full year. StoneCo — The financial technology stock rose 2.6% following an upgrade to overweight from neutral by JPMorgan . Ultragenyx Pharmaceutical — The biopharma stock added nearly 4% following an upgrade to buy from neutral at Goldman Sachs. Shopify — The e-commerce technology stock slipped 1.6% on the back of a MoffettNathanson downgrade to neutral from buy.
Persons: Goldman Sachs, Smartsheet, LSEG, Sprinklr, Mizuho, there's, StoneCo, CH Robinson, Goldman, ISI's, Shopify, Guggenheim, —, Jesse Pound, Michelle Fox, Lisa Kailai Han Organizations: Nvidia, LSEG, Revenue, Mizuho, JPMorgan, Ultragenyx Pharmaceutical, Goldman, eBay, Citi, UBS, BMO Capital, BMO, Viridian Therapeutics, ISI, Energy Locations: Americas
☆ Wells Fargo says this little-known biotech company could rally more than 80%
  + stars: | 2023-04-17 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +1 min
Viridian Therapeutics is "a sight for sore eyes," according to Wells Fargo. Viridian's thyroid eye disease treatment VRDN-001 is currently undergoing clinical testing. Wells Fargo is confident it will gain market share even with Horizon's Tepezza already established in the market. Results for VRDN-001's phase one and two trials in chronic thyroid eye disease are expected in the second half of 2023. VRDN 1Y mountain Viridian Therapeutics stock —CNBC's Michael Bloom contributed to this report.
0 next >>
Total: 2